These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38327091)

  • 1. Global pannexin 1 deletion increases tumor-infiltrating lymphocytes in the BRAF/Pten mouse melanoma model.
    Sanchez-Pupo RE; Finch GA; Johnston DE; Craig H; Abdo R; Barr K; Kerfoot S; Dagnino L; Penuela S
    Mol Oncol; 2024 Apr; 18(4):969-987. PubMed ID: 38327091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BRAFV600E in an inducible murine model of melanoma.
    Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU
    Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten
    Deken MA; Song JY; Gadiot J; Bins AD; Kroon P; Verbrugge I; Blank CU
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
    Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
    Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic BRAF
    Shabaneh TB; Molodtsov AK; Steinberg SM; Zhang P; Torres GM; Mohamed GA; Boni A; Curiel TJ; Angeles CV; Turk MJ
    Cancer Res; 2018 Sep; 78(17):5038-5049. PubMed ID: 30026331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RAC1 Target NCKAP1 Plays a Crucial Role in the Progression of Braf;Pten-Driven Melanoma in Mice.
    Swaminathan K; Campbell A; Papalazarou V; Jaber-Hijazi F; Nixon C; McGhee E; Strathdee D; Sansom OJ; Machesky LM
    J Invest Dermatol; 2021 Mar; 141(3):628-637.e15. PubMed ID: 32777214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination immunotherapy including OncoVEX
    Gartrell RD; Blake Z; Rizk EM; Perez-Lorenzo R; Weisberg SP; Simoes I; Esancy C; Fu Y; Davari DR; Barker L; Finkel G; Mondal M; Minns HE; Wang SW; Fullerton BT; Lozano F; Chiuzan C; Horst B; Saenger YM
    Cancer Immunol Immunother; 2022 Aug; 71(8):1837-1849. PubMed ID: 34999916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype.
    Penuela S; Gyenis L; Ablack A; Churko JM; Berger AC; Litchfield DW; Lewis JD; Laird DW
    J Biol Chem; 2012 Aug; 287(34):29184-93. PubMed ID: 22753409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
    Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
    Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.
    Frias A; Di Leo L; Antoranz A; Nazerai L; Carretta M; Bodemeyer V; Pagliuca C; Dahl C; Claps G; Mandelli GE; Andhari MD; Pacheco MP; Sauter T; Robert C; Guldberg P; Madsen DH; Cecconi F; Bosisio FM; De Zio D
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation.
    Medina CB; Chiu YH; Stremska ME; Lucas CD; Poon I; Tung KS; Elliott MR; Desai B; Lorenz UM; Bayliss DA; Ravichandran KS
    Immunity; 2021 Aug; 54(8):1715-1727.e7. PubMed ID: 34283971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis.
    Bao L; Sun K; Zhang X
    Channels (Austin); 2021 Dec; 15(1):680-696. PubMed ID: 34796785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
    Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
    Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
    Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
    Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
    Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
    Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.